J Drugs Dermatol
-
Randomized Controlled Trial Multicenter Study
Efficacy and safety of ustekinumab in Chinese patients with moderate to severe plaque-type psoriasis: results from a phase 3 clinical trial (LOTUS).
Available biologic agents for the treatment of psoriasis in China are limited. ⋯ Consistent with results previously reported in global phase 3 studies, ustekinumab was highly effective and generally well tolerated in Chinese patients with moderate to severe psoriasis through 36 weeks.